Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Oncocyte Corporation (OCX) Insider Trading Activity
Healthcare • Diagnostics & Research • 43 employees
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Total Value
$23,897,137.07
Total Shares
6,484,743
Average Trade Value
$1,493,571.07
Most Active Insider
Broadwood Partners, L.P.
Total Activity: $21,179,349
Largest Single Transaction
$9,236,250
by Broadwood Partners, L.P. on Feb 6, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Financial Officer
Officer
|
Feb 7, 2025 | 97,561 | $200,000 | 151,231 (+64.5%) | Purchase | |
|
10% Owner
|
Feb 7, 2025 | 1,077,600 | $2,209,080 | 2,872,671 (+37.5%) | Purchase | |
|
10% Owner
|
Feb 6, 2025 | 0 | $1,353,424 | 6,904,612 | Purchase | |
|
10% Owner
|
Feb 6, 2025 | 4,505,488 | $9,236,250 | 11,410,100 (+39.5%) | Purchase | |
|
10% Owner
|
Feb 6, 2025 | 0 | $9,236,250 | 11,410,100 | Purchase | |
|
10% Owner
|
Feb 6, 2025 | 660,207 | $1,353,424 | 6,904,612 (+9.6%) | Purchase | |
|
10% Owner
|
Feb 4, 2025 | 25 | $51 | 1,795,071 (+0.0%) | Purchase | |
|
10% Owner
|
Jan 31, 2025 | 890 | $1,789 | 1,795,046 (+0.0%) | Purchase | |
|
10% Owner
|
Jan 30, 2025 | 318 | $639 | 1,794,156 (+0.0%) | Purchase | |
|
10% Owner
|
Jan 29, 2025 | 3,880 | $7,799 | 1,793,838 (+0.2%) | Purchase | |
|
10% Owner
|
Jan 14, 2025 | 10,286 | $22,115 | 1,789,958 (+0.6%) | Purchase | |
|
10% Owner
|
Jan 14, 2025 | 100 | $208 | 1,779,672 (+0.0%) | Purchase | |
|
10% Owner
|
Jan 13, 2025 | 5,669 | $11,792 | 1,779,572 (+0.3%) | Purchase | |
|
Director
|
Dec 26, 2024 | 12,500 | $26,350 | 81,554 (+15.3%) | Purchase | |
|
10% Owner
|
Dec 26, 2024 | 90,219 | $192,166 | 1,773,903 (+5.1%) | Purchase | |
|
Chief Financial Officer
Officer
|
Dec 5, 2024 | 20,000 | $45,800 | 53,670 (+37.3%) | Purchase |